Adial Pharmaceuticals (ADIL)
(Delayed Data from NSDQ)
$1.46 USD
-0.04 (-2.61%)
Updated May 21, 2024 10:30 AM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
ADIL 1.46 -0.04(-2.61%)
Will ADIL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ADIL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADIL
Is Masimo (MASI) Outperforming Other Medical Stocks This Year?
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy
ADIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adial (ADIL) Shares Up 43% in the Past Week: Here's Why
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for ADIL
Adial Pharmaceuticals reports Q1 results
ADIL Stock Earnings: Adial Pharmaceuticals Misses EPS for Q1 2024
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals expects cash to fund operations into Q1 of 2025
Adial Pharmaceuticals Finalizes Separation Agreement with Dr. Johnson